Community/Retail

Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.

This month features asciminib (Scemblix), pilocarpine HCI ophthalmic solution (Vuity), and amphetamine (Dyanavel XR).